1. Home
  2. MESO vs CHCO Comparison

MESO vs CHCO Comparison

Compare MESO & CHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$13.93

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo City Holding Company

CHCO

City Holding Company

HOLD

Current Price

$130.76

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MESO
CHCO
Founded
2004
1957
Country
Australia
United States
Employees
81
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
MESO
CHCO
Price
$13.93
$130.76
Analyst Decision
Strong Buy
Hold
Analyst Count
1
2
Target Price
N/A
$132.50
AVG Volume (30 Days)
136.6K
72.3K
Earning Date
02-26-2026
04-23-2026
Dividend Yield
N/A
2.87%
EPS Growth
N/A
13.18
EPS
N/A
2.20
Revenue
N/A
N/A
Revenue This Year
$629.74
$5.16
Revenue Next Year
$30.65
$3.12
P/E Ratio
N/A
$58.43
Revenue Growth
N/A
N/A
52 Week Low
$9.88
$113.21
52 Week High
$21.50
$133.59

Technical Indicators

Market Signals
Indicator
MESO
CHCO
Relative Strength Index (RSI) 42.02 68.17
Support Level $13.71 $120.54
Resistance Level $16.14 $131.33
Average True Range (ATR) 0.47 2.31
MACD -0.07 0.61
Stochastic Oscillator 11.08 95.12

Price Performance

Historical Comparison
MESO
CHCO

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

About CHCO City Holding Company

City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.

Share on Social Networks: